Reducing prostaglandin E(2) production to raise cancer immunogenicity

Cyclooxygenases (COX), commonly upregulated in numerous cancers, generate prostaglandin E(2) (PGE(2)), which has been implicated in key aspects of malignant growth including proliferation, invasion and angiogenesis. Recently, we showed that production of PGE(2) by cancer cells dominantly enables pro...

Descripción completa

Detalles Bibliográficos
Autores principales: Zelenay, Santiago, Reis e Sousa, Caetano
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2016
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4910741/
https://www.ncbi.nlm.nih.gov/pubmed/27467936
http://dx.doi.org/10.1080/2162402X.2015.1123370
_version_ 1782438048722583552
author Zelenay, Santiago
Reis e Sousa, Caetano
author_facet Zelenay, Santiago
Reis e Sousa, Caetano
author_sort Zelenay, Santiago
collection PubMed
description Cyclooxygenases (COX), commonly upregulated in numerous cancers, generate prostaglandin E(2) (PGE(2)), which has been implicated in key aspects of malignant growth including proliferation, invasion and angiogenesis. Recently, we showed that production of PGE(2) by cancer cells dominantly enables progressive tumor growth via immune escape and that cyclooxygenase inhibitors synergize with immunotherapy to enhance tumor eradication.
format Online
Article
Text
id pubmed-4910741
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-49107412016-06-29 Reducing prostaglandin E(2) production to raise cancer immunogenicity Zelenay, Santiago Reis e Sousa, Caetano Oncoimmunology Author's View Cyclooxygenases (COX), commonly upregulated in numerous cancers, generate prostaglandin E(2) (PGE(2)), which has been implicated in key aspects of malignant growth including proliferation, invasion and angiogenesis. Recently, we showed that production of PGE(2) by cancer cells dominantly enables progressive tumor growth via immune escape and that cyclooxygenase inhibitors synergize with immunotherapy to enhance tumor eradication. Taylor & Francis 2016-01-04 /pmc/articles/PMC4910741/ /pubmed/27467936 http://dx.doi.org/10.1080/2162402X.2015.1123370 Text en © 2016 The Author(s). Published with license by Taylor & Francis Group, LLC http://creativecommons.org/licenses/by-nc/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License http://creativecommons.org/licenses/by-nc/3.0/, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. The moral rights of the named author(s) have been asserted.
spellingShingle Author's View
Zelenay, Santiago
Reis e Sousa, Caetano
Reducing prostaglandin E(2) production to raise cancer immunogenicity
title Reducing prostaglandin E(2) production to raise cancer immunogenicity
title_full Reducing prostaglandin E(2) production to raise cancer immunogenicity
title_fullStr Reducing prostaglandin E(2) production to raise cancer immunogenicity
title_full_unstemmed Reducing prostaglandin E(2) production to raise cancer immunogenicity
title_short Reducing prostaglandin E(2) production to raise cancer immunogenicity
title_sort reducing prostaglandin e(2) production to raise cancer immunogenicity
topic Author's View
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4910741/
https://www.ncbi.nlm.nih.gov/pubmed/27467936
http://dx.doi.org/10.1080/2162402X.2015.1123370
work_keys_str_mv AT zelenaysantiago reducingprostaglandine2productiontoraisecancerimmunogenicity
AT reisesousacaetano reducingprostaglandine2productiontoraisecancerimmunogenicity

Ejemplares similares